|
Age (years)
|
|
Mean ± standard deviation
|
58.4 ± 10.2
| |
|
Median (range)
|
59 (29–78)
| |
|
ECOG performance status on chemotherapy day 1
|
|
0
|
42
|
39
|
|
1
|
57
|
53
|
|
2
|
8
|
7
|
|
HER2 overexpression
|
|
2+/FISH +
|
8
|
7
|
|
3+
|
97
|
90
|
|
FISH +/no immunohistochemistry or other
|
3
|
3
|
|
Tumor grade (n = 102)
|
|
G1
|
2
|
2
|
|
G2
|
47
|
46
|
|
G3
|
53
|
52
|
|
Metastatic sites at onset of study treatment (n)
|
|
Mean ± standard deviation
|
1.8 ± 0.9
| |
|
Median, range
|
2 (1–5)
| |
|
Organ site involvement
|
|
Local/skin
|
14
|
13
|
|
Lymph nodes, non-regional
|
20
|
19
|
|
Bone
|
41
|
38
|
|
Liver
|
48
|
44
|
|
Lung
|
49
|
45
|
|
Pleural effusion
|
13
|
12
|
|
Genitourinary
|
1
|
1
|
|
Other
|
9
|
8
|
|
Previous treatment
|
|
Neoadjuvant chemotherapy
|
11
|
10
|
|
Adjuvant chemotherapy
|
74
|
69
|
|
Adjuvant endocrine therapy
|
45
|
42
|
|
Palliative chemotherapy
|
40
|
37
|
|
Palliative endocrine therapy
|
34
|
31
|
